期刊文献+

活化细胞黏附分子在甲状腺癌中的表达及其临床意义

Expression and clinical significance of activated-leukocyte adhesion molecule in thyroid carcinoma
原文传递
导出
摘要 目的:研究活化细胞黏附分子(ALCAM)在甲状腺癌组织中表达及其临床意义。方法:免疫组织化学法检测52例甲状腺癌组织及对应癌旁正常甲状腺组织中ALCAM的表达,比较ALCAM在两种组织中表达的差异,并分析其表达与甲状腺癌患者临床病理因素及预后的关系。结果:ALCAM在甲状腺癌组织中的阳性表达率明显高于癌旁正常甲状腺组织(71.2%vs.34.6%,P<0.05),但在ALCAM在甲状腺癌组织中表达越低,甲状腺癌组织病理分化程度越低,患者5年总生存率越低(均P<0.01)。结论:ALCAM表达增高可能参与甲状腺癌发生发展进程,然而,在恶性度高、预后差的甲状腺癌的肿瘤组织中ALCAM表达反而降低的原因推测可能与其脱落释放入血有关。 Objective:To investigate the expression of activated-leukocyte adhesion molecule(ALCAM) in thyroid cancer tissue and the clinical significance.Methods:ALCAM expressions in 52 samples of paired thyroid cancer and adjacent normal thyroid tissues were detected by immuohistochemical staining.The ALCAM expression difference between the two types of tissues was compared,and relations of ALCAM expression with clinicopathologic features and prognosis of the thyroid cancer patients were analyzed.Results:The positive ALCAM expression rate in thyroid cancer tissue was significantly higher than that in adjacent normal thyroid tissue(71.2%vs.34.6%,P〈0.05),but in thyroid cancer tissue,the lower ALCAM expression was associated with poorer histopathological differentiation of the thyroid cancer,and shorter 5-year overall survival of the patients(both P〈0.01).Conclusion:Increased ALCAM expression may be involved with the occurrence and development of thyroid cancer.However,the phenomenon of ALCAM expression contrarily reduced in tumor tissues from highly malignant and poor prognostic thyroid cancer is speculated to be related to its detachment and release into the circulation.
出处 《中国普通外科杂志》 CAS CSCD 北大核心 2015年第11期1571-1576,共6页 China Journal of General Surgery
基金 福建省卫生厅青年科研课题基金资助项目(2013-2-130)
关键词 甲状腺肿瘤 活化白细胞黏附分子 预后 Thyroid Neoplasms Activated-Leukocyte Cell Adhesion Molecule Prognosis
  • 相关文献

参考文献21

  • 1裴波,尚艺泰,寸英丽.甲状腺癌肿瘤干细胞的研究进展[J].中国普通外科杂志,2015,24(5):723-727. 被引量:2
  • 2Weidle UH, Eggle D, Klostermann S, et al. ALCAM/CD166: cancer-related issues[J]. Cancer Genomics Proteomics, 2010, 7(5):231-243.
  • 3Hein S, MOiler V, KOhler N, et al. Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue[J]. Breast Cancer Res Treat, 2011,129(2):347-360.
  • 4Chitteti BR, Bethel M, Kacena MA, et al. CD166 and regulation of hematopoiesis[J]. Curr Opin Hematol, 2013, 20(4):273-280.
  • 5Miccich6 F, Da Riva L, Fabbi M, et al. Activated leukocyte cell adhesion molecule expression and shedding in thyroid tumors[J]. PLoS One, 2011, 6(2):e17141. doi: 10,1371/journal.pone.0017141.
  • 6Jezierska A, Matysiak W, Motyl T. ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy[J]. Med Sci Monit, 2006, 12(8):BR263-273.
  • 7Rauch S J, Rosenkranz AC, B6hm A, et al. Cholesterol induces apoptosis-associated loss of the activated leukocyte cell adhesion molecule (ALCAM) in human monocytes[J]. Vascul Pharmaeol, 2011, 54(3/6):93-99.
  • 8Rajasekhar VK, Studer L, Gerald W, et al. Tumour-initiating stem- like cells in human prostate cancer exhibit increased NF-kappaB signalling[J]. Nat Commun, 2011, 2:162.
  • 9Jiao J, Hindoyan A, Wang S, et al. Identification of CD166 as a surface marker for enriching prostate stem/progenitor and cancer initiating cells[J]. PLoS One, 2012, 7(8):e42564. doi: 10,1371/ journal.pone.0042564.
  • 10Zhang WC, Shyh-Chang N, Yang H, et al. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis[J]. Cell, 2012, 148(1/2):259-272.

二级参考文献44

  • 1Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(1):9-29.
  • 2Enewold L, Zhu K, Ron E, et a1. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005[J]. Cancer Epidemiol Biomarkers Prev, 2009, 18(3):784-791.
  • 3Pasquali D, Santoro A, Bufo P, et a1. Upregulation of endocdne gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative pattems,lymph node metastases, and BRAF mutation[J]. Thymid, 2011, 21(4):39l-399.
  • 4Edafe O, Wadsley J, Harrison BJ, et a1. Treatment related morbidity in differentiated thyroid cancer-a survey of clinicians[J]. Thyroid Res, 2014, 7(1):3.
  • 5Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells-perspectives on current status and future directions:AACR Workshop on cancer stem cells[J]. Cancer Res, 2006, 66(19):9339-9344.
  • 6Lapidot T, Sirard C, Vormoor J, et a1. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice[J]. Nature, 1994, 367(6464):645-648.
  • 7Al-Hajj M, Wicha MS, Benito-Hernandez A, et a1. Prospective identification of tumorigenic breast cancer cells[J]. Proc Natl Acad Sci U S A, 2003, 100(7):3983-3988.
  • 8Singh SK, Hawkins C, Clarke ID, et a1. Identification of human brain tumour initiating cells[J]. Nature, 2004, 432(7015):396-401.
  • 9Patrawala L, Calhoun T, Schneider-Broussard R, et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells[J]. Oncogene, 2006, 25(12):1696-1708.
  • 10O'Brien CA, Pollett A, Gallinger S, et al. A human colon cancer capable of initiating tumour growth in immunodeficient mice[J]. Nature, 2006, 445(7123):106-110.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部